CELZ - Why Is Diabetes Focused Creative Medical Stock Surging On Thursday? | Benzinga
Thursday, Creative Medical Technology Holdings Inc (NASDAQ:CELZ) secured FDA authorization for an expanded access therapy using CELZ-201, a cell-based program to manage abnormal glucose tolerance and prevent Type 1 diabetes (T1D) in high-risk individuals.
The therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.
This personalized medicine approach focuses on a single ...